1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Acute Heart Failure-Pipeline Insights, 2017

Acute Heart Failure-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Acute Heart Failure-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Acute Heart Failure. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Acute Heart Failure. DelveInsight’s Report also assesses the Acute Heart Failure therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Acute Heart Failure
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Acute Heart Failure pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Acute Heart Failure and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Acute Heart Failure-Pipeline Insights, 2017
Illustrative

- Acute Heart Failure Overview
- Acute Heart Failure Pipeline Therapeutics
- Acute Heart Failure Therapeutics under Development by Companies
- Acute Heart Failure Filed and Phase III Products
- Comparative Analysis
- Acute Heart Failure Phase II Products
- Comparative Analysis
- Acute Heart Failure Phase I and IND Filed Products
- Comparative Analysis
- Acute Heart Failure Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Acute Heart Failure - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Acute Heart Failure - Discontinued Products
- Acute Heart Failure - Dormant Products
- Companies Involved in Therapeutics Development for Acute Heart Failure
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Acute Heart Failure, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Acute Heart Failure Assessment by Monotherapy Products
- Acute Heart Failure Assessment by Combination Products
- Acute Heart Failure Assessment by Route of Administration
- Acute Heart Failure Assessment by Stage and Route of Administration
- Acute Heart Failure Assessment by Molecule Type
- Acute Heart Failure Assessment by Stage and Molecule Type
- Acute Heart Failure Therapeutics - Discontinued Products
- Acute Heart Failure Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Acute Heart Failure, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Acute Heart Failure Assessment by Monotherapy Products
- Acute Heart Failure Assessment by Combination Products
- Acute Heart Failure Assessment by Route of Administration
- Acute Heart Failure Assessment by Stage and Route of Administration
- Acute Heart Failure Assessment by Molecule Type
- Acute Heart Failure Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Acute heart failure (AHF)- Market Insights, Epidemiology and Market Forecast-2023

Acute heart failure (AHF)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute heart failure (AHF) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Global Congestive Heart Failure (CHF) Treatment Devices Market Analysis & Trends - Industry Forecast to 2025

Global Congestive Heart Failure (CHF) Treatment Devices Market Analysis & Trends - Industry Forecast to 2025

  • $ 4200
  • Industry report
  • January 2017
  • by Accuray Research LLP

The Global Congestive Heart Failure (CHF) Treatment Devices Market is poised to grow at a CAGR of around 6.4% over the next decade to reach approximately $17.8 billion by 2025. Some of the prominent trends ...


Download Unlimited Documents from Trusted Public Sources

Diabetes Statistics and Dermatological Condition Statistics in Pakistan

  • February 2017
    6 pages
  • Diabetes  

    Dermatological ...  

  • Pakistan  

View report >

Endocrine Disease Statistics in the US

  • February 2017
    115 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Diabetes and Stroke Statistics in the UK - Forecast

  • February 2017
    4 pages
  • Diabetes  

    Stroke  

    Cardiovascular ...  

  • United Kingdom  

View report >

Related Market Segments :

Heart Failure

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.